Cisplatin-Induced Rodent Model of Kidney Injury: Characteristics and Challenges

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2018 Oct 3

PMID 30276200

Citations 87

Authors

Martina Perse

Zeljka Veceric-Haler

Affiliations

Soon will be listed here.

Abstract

Cisplatin is an antitumor drug used in the treatment of a wide variety of malignancies. However, its primary dose-limiting side effect is kidney injury, which is a major clinical concern. To help understand mechanisms involved in the development of kidney injury, cisplatin rodent model has been developed. Given the complex pathogenesis of kidney injury, which involves both local events in the kidney and interconnected and interdependent systemic effects in the body, cisplatin rodent model is indispensable in the investigation of underlying mechanisms and potential treatment strategies of both acute and chronic kidney injury. Cisplatin rodent model is well appreciated and widely used model due to its simplicity. It has many similarities to human cisplatin nephrotoxicity, which are mentioned in the paper. In spite of its simplicity and wide applicability, there are also traps that need to be taken into account when using cisplatin model. The present paper is aimed at giving a concise insight into the complex characteristics of cisplatin rodent model and heterogeneity of cisplatin dosage regimens as well as outlining factors that can severely influence the outcome of the model and the study. Challenges for future research are also mentioned.

Citing Articles

Urinary bioorthogonal reporters for the monitoring of the efficacy of chemotherapy for lung cancer and of associated kidney injury.

Cheng P, Zeng Z, Liu J, Liew S, Hu Y, Xu M Nat Biomed Eng. 2025; .

PMID: 39880894 DOI: 10.1038/s41551-024-01340-1.

Protective effect of Panax ginseng extract on cisplatin-induced AKI via downregulating cell death associated genes.

Alipanah-Moghadam R, Aghamohammadi V, Seifi S, Esmaeili H, Noroozzadeh S, Jeddi F Sci Rep. 2025; 15(1):3233.

PMID: 39863673 PMC: 11763254. DOI: 10.1038/s41598-025-87447-0.

Lebanese Cannabis sativa L. extract protects from cisplatin-induced nephrotoxicity in mice by inhibiting podocytes apoptosis.

Khalil A, Al Toufaily S, Shebaby W, Hage M, Mroue D, Faour W J Cannabis Res. 2025; 7(1):3.

PMID: 39819647 PMC: 11737194. DOI: 10.1186/s42238-025-00260-4.

Platinum-based chemotherapies-induced nephrotoxicity: mechanisms, potential treatments, and management.

Shahrahmani F, Badamchizadeh S, Kaihani F, Alavi-Moghadam S, Keshtkari S, Rezaei-Tavirani M Int Urol Nephrol. 2024; .

PMID: 39630371 DOI: 10.1007/s11255-024-04303-2.

Melanocortin-4 receptor antagonist TCMCB07 alleviates chemotherapy-induced anorexia and weight loss in rats.

Zhu X, Potterfield R, Gruber K, Zhang E, Newton S, Norgard M J Clin Invest. 2024; 135(1).

PMID: 39509261 PMC: 11684807. DOI: 10.1172/JCI181305.

References

Yamate J, Sato K, Ide M, Nakanishi M, Kuwamura M, Sakuma S . Participation of different macrophage populations and myofibroblastic cells in chronically developed renal interstitial fibrosis after cisplatin-induced renal injury in rats. Vet Pathol. 2002; 39(3):322-33. DOI: 10.1354/vp.39-3-322. View

Gautier J, Riefke B, Walter J, Kurth P, Mylecraine L, Guilpin V . Evaluation of novel biomarkers of nephrotoxicity in two strains of rat treated with Cisplatin. Toxicol Pathol. 2010; 38(6):943-56. DOI: 10.1177/0192623310379139. View

Baldew G, Van den Hamer C, Los G, Vermeulen N, De Goeij J, McVie J . Selenium-induced protection against cis-diamminedichloroplatinum(II) nephrotoxicity in mice and rats. Cancer Res. 1989; 49(11):3020-3. View

Ravichandran K, Wang Q, Ozkok A, Jani A, Li H, He Z . CD4 T cell knockout does not protect against kidney injury and worsens cancer. J Mol Med (Berl). 2015; 94(4):443-55. DOI: 10.1007/s00109-015-1366-z. View

Santos N, Catao C, Martins N, Curti C, Bianchi M, Santos A . Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. Arch Toxicol. 2007; 81(7):495-504. DOI: 10.1007/s00204-006-0173-2. View

McKeage M, Morgan S, Boxall F, Murrer B, Hard G, HARRAP K . Lack of nephrotoxicity of oral ammine/amine platinum (IV) dicarboxylate complexes in rodents. Br J Cancer. 1993; 67(5):996-1000. PMC: 1968463. DOI: 10.1038/bjc.1993.182. View

Simmons E, Himmelfarb J, Sezer M, Chertow G, Mehta R, Paganini E . Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004; 65(4):1357-65. DOI: 10.1111/j.1523-1755.2004.00512.x. View

Rebillard A, Rioux-Leclercq N, Muller C, Bellaud P, Jouan F, Meurette O . Acid sphingomyelinase deficiency protects from cisplatin-induced gastrointestinal damage. Oncogene. 2008; 27(51):6590-5. DOI: 10.1038/onc.2008.257. View

Wang E, Snyder R, Fielden M, Smith R, Gu Y . Validation of putative genomic biomarkers of nephrotoxicity in rats. Toxicology. 2008; 246(2-3):91-100. DOI: 10.1016/j.tox.2007.12.031. View

10.

Yang C, Kaushal V, Haun R, Seth R, Shah S, Kaushal G . Transcriptional activation of caspase-6 and -7 genes by cisplatin-induced p53 and its functional significance in cisplatin nephrotoxicity. Cell Death Differ. 2007; 15(3):530-44. DOI: 10.1038/sj.cdd.4402287. View

11.

Bodenner D, Dedon P, Keng P, Katz J, Borch R . Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate. Cancer Res. 1986; 46(6):2751-5. View

12.

Townsend D, Hanigan M . Inhibition of gamma-glutamyl transpeptidase or cysteine S-conjugate beta-lyase activity blocks the nephrotoxicity of cisplatin in mice. J Pharmacol Exp Ther. 2001; 300(1):142-8. PMC: 6522257. DOI: 10.1124/jpet.300.1.142. View

13.

Yamate J, Ishida A, Tsujino K, Tatsumi M, Nakatsuji S, Kuwamura M . Immunohistochemical study of rat renal interstitial fibrosis induced by repeated injection of cisplatin, with special reference to the kinetics of macrophages and myofibroblasts. Toxicol Pathol. 1996; 24(2):199-206. DOI: 10.1177/019262339602400208. View

14.

Levey A, Inker L . Assessment of Glomerular Filtration Rate in Health and Disease: A State of the Art Review. Clin Pharmacol Ther. 2017; 102(3):405-419. DOI: 10.1002/cpt.729. View

15.

Yonezawa A, Masuda S, Nishihara K, Yano I, Katsura T, Inui K . Association between tubular toxicity of cisplatin and expression of organic cation transporter rOCT2 (Slc22a2) in the rat. Biochem Pharmacol. 2005; 70(12):1823-31. DOI: 10.1016/j.bcp.2005.09.020. View

16.

Pinches M, Betts C, Bickerton S, Beattie L, Burdett L, Thomas H . Evaluation of novel urinary renal biomarkers with a cisplatin model of kidney injury: effects of collection period. Toxicol Pathol. 2012; 40(3):534-40. DOI: 10.1177/0192623311432437. View

17.

Jia Z, Wang N, Aoyagi T, Wang H, Liu H, Yang T . Amelioration of cisplatin nephrotoxicity by genetic or pharmacologic blockade of prostaglandin synthesis. Kidney Int. 2010; 79(1):77-88. DOI: 10.1038/ki.2010.331. View

18.

Levi F, Hrushesky W, Halberg F, Langevin T, Haus E, Kennedy B . Lethal nephrotoxicity and hematologic toxicity of cis-diamminedichloroplatinum ameliorated by optimal circadian timing and hydration. Eur J Cancer Clin Oncol. 1982; 18(5):471-7. DOI: 10.1016/0277-5379(82)90116-x. View

19.

Jodrell D, Newell D, Morgan S, Clinton S, BENSTED J, HUGHES L . The renal effects of N10-propargyl-5,8-dideazafolic acid (CB3717) and a non-nephrotoxic analogue ICI D1694, in mice. Br J Cancer. 1991; 64(5):833-8. PMC: 1977485. DOI: 10.1038/bjc.1991.409. View

20.

Ramesh G, Reeves W . p38 MAP kinase inhibition ameliorates cisplatin nephrotoxicity in mice. Am J Physiol Renal Physiol. 2005; 289(1):F166-74. DOI: 10.1152/ajprenal.00401.2004. View